Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Burkitt Lymphoma 5Prostatic Neoplasms 4Neoplasms 4Leukemia, Biphenotypic, Acute 4Ovarian Neoplasms 3Lymphoma, Follicular 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Metastatic Castration-resistant Prostate Cancer 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Lymphoma 2Hodgkin Disease 2Endometrial Neoplasms 2Down Syndrome 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Myasthenia Gravis 1Lymphoma, T-Cell, Peripheral 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Bulbo-Spinal Atrophy, X-Linked 1Biliary Tract Neoplasms 1Adrenal Insufficiency 1

Interventions

Cyclophosphamide 3Vincristine 2Prednisone 2Etoposide 2Doxorubicin 2tazemetostat 1pembrolizumab 1fludarabine 1etoposide phosphate 1duvelisib 1Prednisolone 1Melphalan 1Cytarabine 1Carmustine 1Azacitidine 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enteropathy-Associated T-Cell Lymphoma × Prednisolone × 90 days × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡